#ASH22: 'Not so surprising': With lack of durability, Affimed scraps monotherapy plans in favor of NK cell combo
NEW ORLEANS — Affimed won’t move ahead with an accelerated approval application for its drug AFM13, an innate cell engager it was testing in relapsed/refractory peripheral T-cell lymphoma, after a lackluster trial result.
The company released toplines from its Phase II trial on Saturday. Patients in the trial had a 32.4% objective response rate to AFM13 as a monotherapy, but a median duration of response of only 2.3 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.